Open AccessBreakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole
Author(s) -
Caitlin R. Rausch,
Adam J. DiPippo,
Prithviraj Bose,
Dimitrios P. Kontoyiannis
Publication year - 2018
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciy406
Subject(s) - mucormycosis , medicine , neutropenia , leukemia , aspergillosis , amphotericin b , mycosis , immunology , dermatology , chemotherapy , antifungal , surgery
We retrospectively assessed breakthrough invasive fungal infections (b-IFIs) in 100 consecutive patients with leukemia receiving single-agent isavuconazole; 13 had documented b-IFIs (candidiasis in 6, mucormycosis in 4). All b-IFIs were observed in patients with prolonged neutropenia and active leukemia.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom